Skip to main content
Premium Trial:

Request an Annual Quote

Applied BioCode, Diatherix Ink Partnership, Supply Agreement

NEW YORK (GenomeWeb) - Applied BioCode and Diatherix Laboratories today announced that they have signed a partnership and supply agreement to develop multiplex molecular diagnostic panels for laboratory testing.

Applied BioCode, a privately held biotechnology company, develops, manufactures, and markets barcoded magnetic beads (BMB) and detection systems to facilitate development of highly multiplexed nucleic acid or protein detection assays. Diatherix Laboratories, located in the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama, operates as an independent, CAP-accredited clinical laboratory that provides advanced multiplex molecular diagnostic services.

Diatherix will utilize its TEM-PCR technology with Applied BioCode's BMB technology and detection systems to develop highly sensitive multiplex molecular diagnostic panels for infectious disease laboratory testing.

"We are pleased to partner with Applied BioCode for their barcoded magnetic bead technology," Diatherix CEO Dennis Grimaud said in a statement. The technology, he added, will allow Diatherix "to reduce the development timeframe to bring new multiplex test panels to market and enhance the sensitivity of our molecular diagnostic panels."

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.